Founder of SmithOnStocks
Contributor's Links: SmithOnStocks

My name is Larry Smith. I spent the first 25 years of my career working on Wall Street as an analyst with a primary focus on biotechnology and pharmaceutical stocks. However, I have also covered companies in several other industries. Most of this time was spent with Smith Barney and Hambrecht ... more

ALL CONTRIBUTIONS

Northwest Biotherapeutics: Thoughts On Why The Phase 3 Trial Of DCVax-L Is Ongoing
The phase 3 trial of DCVax-L in newly diagnosed glioblastoma is continuing even though it has passed the 248 PFS events (mPFS is a primary endpoint) and has probably surpassed 233 OS events (mOS is an independent co-primary endpoint).
Read
Northwest Biotherapeutics, Bristol-Myers Squibb: Success For The Yervoy-Opdivo Combination
The stoppage at an interim analysis of Bristol-Myers Squibb’s’ Checkmate-214 trial provides meaningful information into assessing the potential for success of Northwest Biotherapeutics.
Read
Portola: Potential Launch Date For Bevyxxa And Price Announcement
Portola ended 2Q, 2017 with $270 million of cash which management states can fund operations into 1Q, 2018. The Company is going to require a very significant amount of cash to fund the launch of Bevyxxa and AndexXa.
Read
Northwest Biotehrpeutics: How Does DCVax-L Clinical Data Compare To The CAR-T Therapy Axi-Cel?
It is a paradox that people can look at the Kite phase 2 data on Axi-Cel and pronounce it as stunning as does Biotech Hawk and in the next breath dismiss phase 1/2 data on DCVax-L that appears much more encouraging.
Read
Alimera Sciences: Company Achieves Breakeven Pretax Cash Flow In 2Q, 2017 Despite Slow Unit Demand For Iluvien
Alimera has made dramatic improvements in its cash flow situation and has done a very respectable job in building sales. Alimera is not far away from being a cash generating, profitable pharmaceutical company.
Read
Cryoport: As Its Clients Transition From Clinical Development To Commercial, Growth Could Be Explosive
Cryoport is in the very early stages of corporate development and has only minimal sales ($9.8 million on a trailing twelve months basis). It is still too small to catch the eyes of large investors.
Read

STOCKS I FOLLOW

ACHN Achillion Pharmaceuticals Inc.
AGEN Agenus Inc.
ALIM Alimera Sciences Inc.
ARNA Arena Pharmaceuticals, Inc.
ATHX Athersys Inc.
BDSI BioDelivery Sciences International Inc.
BMY Bristol-Myers Squibb Company
CLDX Celldex Therapeutics Inc
CMRX Chimerix, Inc.
CPRX Catalyst Pharmaceutical Partners Inc.
CUR Neuralstem, Inc.
CYRX CRYOPORT INC
CYTK Cytokinetics, Incorporated
DNDN Dendreon Corporation
DSCI DERMA SCIENCES INC
GSK GlaxoSmithKline
HRTX Heron Therapeutics, Inc.
IMUC IMMUNOCELLULAR THERA
INO Inovio Pharmaceuticals, Inc.
INSV Insite Vision Inc
JNJ Johnson & Johnson
MAPP MAP Pharmaceuticals Inc.
MNK Mallinckrodt Plc Ordinary Shares
MRK Merck & Co Inc.
NBY NovaBay Pharmaceuticals, Inc.
NWBO NORTHWEST BIOTH NEW
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Owner
Smith On Stocks
September 2004 - Present (14 years 9 months)
Managing Director
Hambrecht & Quist
August 1990 - June 1995 (4 years 11 months)

I was an analyst specializing in biotechnology and pharmaceuticals. I was also director of health care research and a member of the operating committee. I ran the H&Q healthcare conference during my time at the firm.

Pharmaceutical/Biotechnology Analyst
Smith Barney
August 1976 - August 1989 (13 years 3 months)

I first joined Smith Barney as an analyst covering pharmaceutical companies. I was also one of the first analysts to cover biotechnology companies as I was the analyst assigned to cover Amgen when Smith Barney brought that company public. I then went on to become Senior Managing Director, Director of Research and member of the board of directors.

Education

Columbia University- Columbia Business School
MBD
1970 / 1971
Finance
Stanford University
MS
1969 / 1970
Mechanical Engineering

Publications